BeyondSpring Inc. Operating Cash Flow
BeyondSpring Inc. (BYSI) reported Operating Cash Flow of -$7.05 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-14
- BeyondSpring Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$3.77M.
- BeyondSpring Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$3.28M.
- BeyondSpring Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$5.50M, a 660.49% decline year-over-year.
- BeyondSpring Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$4.19M.
- BeyondSpring Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$19.77M.
- BeyondSpring Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$16.44M.
- BeyondSpring Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$16.47M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$3.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$7.05M 10-Q · filed 2026-08-14 | -$12.55M derived: sum of 3 quarters · filed 2026-08-14 | -$16.75M derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$3.28M 10-Q · filed 2026-05-13 | -$8.78M derived: sum of 2 quarters · filed 2026-05-13 | -$12.97M derived: sum of 3 quarters · filed 2026-05-13 | -$18.85M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | -$5.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$9.70M derived: sum of 2 quarters · filed 2026-03-25 | -$15.57M derived: sum of 3 quarters · filed 2026-08-14 | -$19.77M 10-K · filed 2026-03-25 |
| 2025-09-30 | -$4.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$10.07M derived: sum of 2 quarters · filed 2026-08-14 | -$14.27M 10-Q · filed 2025-11-12 | -$13.28M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$5.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$10.07M 10-Q · filed 2026-08-14 | -$9.09M derived: sum of 3 quarters · filed 2026-08-14 | -$14.26M derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$4.20M 10-Q · filed 2026-05-13 | -$3.22M derived: sum of 2 quarters · filed 2026-05-13 | -$8.39M derived: sum of 3 quarters · filed 2026-05-13 | -$15.37M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $982.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-25 | -$4.19M derived: sum of 2 quarters · filed 2026-03-25 | -$11.17M derived: sum of 3 quarters · filed 2026-03-25 | -$16.44M 10-K · filed 2026-03-25 |
| 2024-09-30 | -$5.17M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | -$12.16M derived: sum of 2 quarters · filed 2025-11-12 | -$17.43M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | -$6.99M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$12.25M 10-Q · filed 2025-08-13 | ||
| 2024-03-31 | -$5.27M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$16.47M 10-K · filed 2025-03-27 | |||
| 2022-12-31 | -$27.46M 20-F · filed 2023-04-18 | |||
| 2021-12-31 | -$16.92M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-18 | -$14.09M derived: sum of 2 quarters · filed 2023-04-18 | -$28.30M derived: sum of 3 quarters · filed 2023-04-18 | -$47.24M 20-F · filed 2023-04-18 |
| 2021-09-30 | $2.83M derived: 6-K 9 month − 6-K 6 month · filed 2021-12-30 | -$11.38M derived: sum of 2 quarters · filed 2021-12-30 | -$30.32M 6-K · filed 2021-12-30 | -$37.29M derived: sum of 4 quarters · filed 2023-04-18 |
| 2021-06-30 | -$14.21M derived: 6-K 6 month − 6-K 3 month · filed 2021-09-10 | -$33.15M 6-K · filed 2021-09-10 | -$40.11M derived: sum of 3 quarters · filed 2023-04-18 | -$51.57M derived: sum of 4 quarters · filed 2023-04-18 |
| 2021-03-31 | -$18.94M 6-K · filed 2021-06-16 | -$25.90M derived: sum of 2 quarters · filed 2023-04-18 | -$37.36M derived: sum of 3 quarters · filed 2023-04-18 | -$51.63M derived: sum of 4 quarters · filed 2023-04-18 |
| 2020-12-31 | -$6.96M derived: 20-F 12 month − 6-K 9 month · filed 2023-04-18 | -$18.42M derived: sum of 2 quarters · filed 2023-04-18 | -$32.70M derived: sum of 3 quarters · filed 2023-04-18 | -$43.74M 20-F · filed 2023-04-18 |
| 2020-09-30 | -$11.46M derived: 6-K 9 month − 6-K 6 month · filed 2021-12-30 | -$25.73M derived: sum of 2 quarters · filed 2021-12-30 | -$36.78M 6-K · filed 2021-12-30 | -$49.47M derived: sum of 4 quarters · filed 2022-04-14 |
| 2020-06-30 | -$14.27M derived: 6-K 6 month − 6-K 3 month · filed 2021-09-10 | -$25.32M 6-K · filed 2021-09-10 | -$38.01M derived: sum of 3 quarters · filed 2022-04-14 | -$60.38M derived: sum of 4 quarters · filed 2022-04-14 |
| 2020-03-31 | -$11.05M 6-K · filed 2021-06-16 | -$23.73M derived: sum of 2 quarters · filed 2022-04-14 | -$46.11M derived: sum of 3 quarters · filed 2022-04-14 | -$54.15M derived: sum of 4 quarters · filed 2022-04-14 |
| 2019-12-31 | -$12.68M derived: 20-F 12 month − 6-K 9 month · filed 2022-04-14 | -$35.06M derived: sum of 2 quarters · filed 2022-04-14 | -$43.10M derived: sum of 3 quarters · filed 2022-04-14 | -$48.16M 20-F · filed 2022-04-14 |
| 2019-09-30 | -$22.38M derived: 6-K 9 month − 6-K 6 month · filed 2020-11-17 | -$30.42M derived: sum of 2 quarters · filed 2020-11-17 | -$35.48M 6-K · filed 2020-11-17 | -$43.80M derived: sum of 4 quarters · filed 2021-04-30 |
| 2019-06-30 | -$8.04M derived: 6-K 6 month − 6-K 3 month · filed 2020-09-03 | -$13.10M 6-K · filed 2020-09-03 | -$21.42M derived: sum of 3 quarters · filed 2021-04-30 | -$31.02M derived: sum of 4 quarters · filed 2021-04-30 |
| 2019-03-31 | -$5.06M 6-K · filed 2020-06-11 | -$13.38M derived: sum of 2 quarters · filed 2021-04-30 | -$22.98M derived: sum of 3 quarters · filed 2021-04-30 | -$36.08M derived: sum of 4 quarters · filed 2021-04-30 |
| 2018-12-31 | -$8.32M derived: 20-F 12 month − 6-K 9 month · filed 2021-04-30 | -$17.91M derived: sum of 2 quarters · filed 2021-04-30 | -$31.02M derived: sum of 3 quarters · filed 2021-04-30 | -$39.95M 20-F · filed 2021-04-30 |
| 2018-09-30 | -$9.60M derived: 6-K 9 month − 6-K 6 month · filed 2019-12-18 | -$22.70M derived: sum of 2 quarters · filed 2019-12-18 | -$31.64M 6-K · filed 2019-12-18 | -$41.82M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-06-30 | -$13.10M derived: 6-K 6 month − 6-K 3 month · filed 2019-09-18 | -$22.04M 6-K · filed 2019-09-18 | -$32.22M derived: sum of 3 quarters · filed 2020-04-30 | -$40.43M derived: sum of 4 quarters · filed 2020-04-30 |
| 2018-03-31 | -$8.94M 6-K · filed 2019-07-10 | -$19.12M derived: sum of 2 quarters · filed 2020-04-30 | -$27.32M derived: sum of 3 quarters · filed 2020-04-30 | -$32.46M derived: sum of 4 quarters · filed 2020-04-30 |
| 2017-12-31 | -$10.18M derived: 20-F 12 month − 6-K 9 month · filed 2020-04-30 | -$18.39M derived: sum of 2 quarters · filed 2020-04-30 | -$23.52M derived: sum of 3 quarters · filed 2020-04-30 | -$28.80M 20-F · filed 2020-04-30 |
| 2017-09-30 | -$8.20M derived: 6-K 9 month − 6-K 6 month · filed 2017-11-09 | -$13.34M derived: sum of 2 quarters · filed 2018-10-23 | -$18.61M 6-K · filed 2017-11-09 | -$23.84M derived: sum of 4 quarters · filed 2019-04-30 |
| 2017-06-30 | -$5.13M derived: 6-K 6 month − 6-K 3 month · filed 2018-10-23 | -$10.41M 6-K · filed 2018-10-23 | -$15.64M derived: sum of 3 quarters · filed 2019-04-30 | |
| 2017-03-31 | -$5.28M 6-K · filed 2018-06-21 | -$10.51M derived: sum of 2 quarters · filed 2019-04-30 | ||
| 2016-12-31 | -$5.23M derived: 20-F 12 month − 6-K 9 month · filed 2019-04-30 | -$13.70M 20-F · filed 2019-04-30 | ||
| 2016-09-30 | -$8.47M 6-K · filed 2017-11-09 | |||
| 2015-12-31 | -$6.57M 20-F · filed 2018-04-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 | |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Context Therapeutics Inc. (CNTX) | United States | $0.034B | -1.10 |
| ROCKWELL MEDICAL, INC. (RMTI) | United States | $0.035B | |
| MIRA PHARMACEUTICALS, INC. (MIRA) | United States | $0.036B | -4.30 |